DOCSLIB.ORG

(12) United States Patent (10) Patent No.: US 8,133,863 B2 Maggio (45) Date of Patent: Mar

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
(12) United States Patent (10) Patent No.: US 8,133,863 B2 Maggio (45) Date of Patent: Mar USOO8133863B2 (12) United States Patent (10) Patent No.: US 8,133,863 B2 Maggio (45) Date of Patent: Mar. 13, 2012 (54) STABILIZING ALKYLGLYCOSIDE 3.5. A g E. S. et al COMPOSITIONS AND METHODS THEREOF 5,369,095 A 1 1/1994 KeeOnahoe et al. et al. 5,556,757 A 9, 1996 A1 tal. (75) Inventor: Edward T. Maggio, San Diego, CA 5,556,940 A 9, 1996 WRC (US) 6,524,557 B1 2/2003 Backstrom et al. 6,551.578 B2 * 4/2003 Adjei et al. ..................... 424/45 (73) Assignee: Aegis Therapeutics, LLC, San Diego, 2002fO1105247,425,542 A1B2 9/20088, 2002 CowanMaggio et al. CA (US) 2004/0209814 A1 10, 2004 Nauck et al. 2005/0215475 A1 9/2005 Ong et al. (*) Notice: Subject to any disclaimer, the term of this 2005/0276843 Al 12/2005 Quay et al. patent is extended or adjusted under 35 2006/0046962 A1 3/2006 Meezan et al. .................. 514/12 2006, OO74025 A1 4/2006 Quay et al. U.S.C. 154(b) by 443 days. 2006/0183674 A1 8/2006 Brand et al. 21) Appl. No.: 12/360,758 2007/01 11938 A1 5, 2007 Pert et al. (21) Appl. No.: 9 (Continued) (22) Filed: Jan. 27, 2009 FOREIGN PATENT DOCUMENTS US 2009/0197816A1 Aug. 6, 2009 (Continued) OTHER PUBLICATIONS Related U.S. Application Data Brown et al. Affinity Purification of a Somatostatin Receptor-G- (60) Division of application No. 12/119,378, filed on May protein Complex... The Journal of Biological Chemistry. Mar. 25. 12, 2008, which is a continuation-in-part of 1993, Vol. 268, pp. 6668-6676. application No. 12/050,038, filed on Mar. 17, 2008 Hovgaardet al., "Stabilization of insulin by alkylmaltosides. A. Spec which is a continuation-in- art of a lication No. troscopic evaluation'. International Journal of Pharmaceutics, p pp 132(1-2): 107-113 (1996). 1 1/474,055, filed on Jun. 23, 2006, now Pat. No. 7,425,542. (Continued) 51) Int. C Primary Examiner — Jeffrey E. Russel (51) 38/08 (2006.01) (74) Attorney, Agent, or Firm — DLA Piper LLP (US) A6 IK38/2 (2006.01) (57) ABSTRACT A6 IK 47/26 (2006.01) The present invention relates to alkylglycoside-containing (52) U.S. Cl. ...................................... 514/11.1: 514/21.1 compositions and methods for increasing the stability, reduc (58) Field of Classification Search ........................ None ing the aggregation and immunogenicity, increasing the bio See application file for complete search history. logical activity, and reducing or preventing fibrillar formation of a peptide, polypeptide, or variant thereof, for example (56) References Cited amylin, a monoclonal antibody, insulin, Peptide T or analog thereof, gastrin, gastrir releasing peptides, gastrin releasing U.S. PATENT DOCUMENTS peptide-like (GRP) proteins, epidermal growth factor orana 4,130,709 A 12/1978 Nagarajan log thereof. 4,440,675 A 4, 1984 Braude 37 Claims, 7 Drawing Sheets Background Information Fibri Oxis Four sheets US 8,133,863 B2 Page 2 U.S. PATENT DOCUMENTS OTHER PUBLICATIONS 2008. O194461 A1 8, 2008 Maggio 2008/0268032 A1 10, 2008 Maggio Hovgaard et al., “Stabilization of insulin by alkylmaltosides. B. Oral 2009/0047347 A1 2, 2009 Maggio absorption in vivo in rats'. International Journal of Pharmaceutics, 2009. O156478 A1 6, 2009 Lau et al. 132(1-2): 115-121 (1996). 2009/0326193 A1 12, 2009 Maggio et al. van der Lubben et al., "Chitosan and its derivatives in mucosal drug and vaccine delivery'. Eur, J. Pharm. Sci., 14(3):201-207 (2001). FOREIGN PATENT DOCUMENTS Mitrano & Newton, “Factors affecting insulin adherence to type I WO WO 2006/025882 A3 3, 2006 glass bottles”, Am. J. Hosp. Pharm., 39(9): 1491-5 (1982). WO WO 2006/051110 A2 5, 2006 WO WO 2006/051110 A3 5, 2006 * cited by examiner U.S. Patent Mar. 13, 2012 Sheet 1 of 7 US 8,133,863 B2 Background Information Fig. 1 U.S. Patent Mar. 13, 2012 Sheet 2 of 7 US 8,133,863 B2 T-contro" 8-8282% A 3.125% A 3 8 -: - & 3.25.0% A k-3.08.2% 8 -X-3:23%. 8: .'-' ' '.' '.' '.'''''''-' ' ' ' ' ' ' ' ' ' ' '-'-'-'s' - - - - - - - - - 3.35.3% 8. U.S. Patent Mar. 13, 2012 Sheet 3 of 7 US 8,133,863 B2 -8-0.062% A -- 0.25% A -- 0,250% A -%-0.082% 8. -8-0.25% B i -- 0.250% B U.S. Patent Mar. 13, 2012 Sheet 4 of 7 US 8,133,863 B2 Gh p 6.5 traya .25% sapie '''''''x''-W-swaxwww.axwww.www.W.W ------------------------------a .....-------as-a-was--------- 3-ph S.S. travai (, 24% St. sapie 188 go-cr; U.S. Patent Mar. 13, 2012 Sheet 5 of 7 US 8,133,863 B2 Coaparisor of irs begside: Effect of Aggregation of peptide {A-3A Stored at 4 Degrees for Preierg period of inte (lot 336238 -8-6-----. .hia - - - - - - degree:- - - - - - : -8-3 week :*:- 2 wa&ks 3 weaks i-x-4 weaks Pepticis ; (383&; lag 8 Fig. 5 U.S. Patent Mar. 13, 2012 Sheet 6 of 7 US 8,133,863 B2 n 3&A Ferraiation; (3.8 rigfa risixties of 3W-3 &A seceign of 8-acre ages: variots reatests for Staixity A3+ APA, not FE Ex, aged A3 - APA/FE x, aged 34. A 8: Afif x, aged : 83+ CAPTA, no TFE Tx, 33 - DAPAf:FE, aged CAPTA aged 34d x BAPIA aged 7d x : wifts ory E8 SE AS s &ewerse raiseritese &xivity *erce of virts City Cerro: y 8.38: 888 & Fig. 6 U.S. Patent Mar. 13, 2012 Sheet 7 of 7 US 8,133,863 B2 {{3} 800 63 f f : ji 40G ? f 200 X. --- 3 : S. 7 & 28, 2 39 43 54; 8: 8? 73 82 88 Rays at 37C, 353 RP8; -e-contro --0.1% dodecy maitoside (less than 10% 8 anomer) - x - -3.2% dodecy; naitoside (less than 30% Sanomer) x . 4% dodecy: iaitoside (greater {ha : 98% 8 artorner) -x- 3.2% 8ociecy: 3:a::side great &f that 88% 3 artorie US 8,133,863 B2 1. 2 STABILIZING ALKYLGLYCOSDE Many products are only effective when delivered by injec COMPOSITIONS AND METHODS THEREOF tion in relatively high concentration. Preventing aggregation has become a major issue for pharmaceutical formulators CROSS REFERENCE TO RELATED since the trend toward high-concentration solutions increases APPLICATION(S) the likelihood of protein-protein interactions favoring aggre gation. Thus, protein aggregation may impact biological This application is a divisional of U.S. application Ser. No. product process yield and potency. Since aggregation is fre 12/119,378, filed May 12, 2008, currently pending: which is quently mediated by higher temperatures, protein therapeu a continuation-in-part of U.S. application Ser. No. 12/050, tics require certain so-called “Cold Chain’ handling require 10 ments to guarantee a continuous chain of refrigerated 038 filed Mar. 17, 2008, currently pending; which is a con temperatures during shipping and storage (DePalma Jan. 15. tinuation-in-part of U.S. application Ser. No. 1 1/474,055 filed 2006). Cold chain requirements significantly increase the Jun. 23, 2006 now U.S. Pat. No. 7,425,542, now issued. The cost of storing and transporting drugs. The present invention entire content of each of the prior applications is incorporated mitigates and, in some cases, may eliminate the need for strict herein by reference. 15 cold-chain maintenance. Over the last five years, the FDA and other regulatory FIELD OF THE INVENTION agencies have increased their scrutiny of aggregation events, and thus biopharmaceutical companies have increased their The present invention relates generally to compositions efforts to understand them. Of particular concernis the induc and methods thereof that increase stability, reduce aggrega tion of unwanted immunogenicity. The immunogenicity of a tion and immunogenicity, increase biological activity, and self-associating peptide can be influenced by the formation of reduce or prevent fibrillar formation of peptides or proteins in aggregates formed as a result of non-covalent intermolecular therapeutically useful formulations, and specifically, to com interactions. For example, interferon has been shown to positions having at least one peptide or protein drug and at aggregate resulting in an antibody response (Hermeling et al. least one alkylglycoside or saccharide alkyl ester Surfactant. 25 2006). The antibody response to erythropoietin has been shown to produce “pure red cell aplasia” in a number of BACKGROUND INFORMATION patients receiving recombinant EPO, (Casadevallet al. 2002) which is potentially a life threatening side effect of EPO Proteins undergo numerous physical and chemical changes therapy. Insulin is well known to lose activity rapidly as a that affect potency and safety. Among these are aggregation, 30 result of protein aggregation upon agitation at temperatures which includes dimerization, trimerization, and higher-order above those found upon refrigerated Storage (Pezron et al. aggregates, plus crystallization and precipitation. Aggrega 2002; Sluzky et al. 1991). Aggregation of recombinant AAV2 tion is rapidly emerging as a key issue underlying multiple results in reduced yield during purification and has deleteri deleterious effects for peptide or protein-based therapeutics, ous effects on immunogenicity following in vivo administra including loss of efficacy, altered pharmacokinetics, reduced 35 tion (Wright 2005). Monoclonal antibody based therapeutics stability or product shelf life, and induction of unwanted have also been shown to be subject to inactivation as a result immunogenicity. In addition, bioavailability and pharmaco of protein aggregation (King et al. 2002). The number of kinetics of a self-associating peptide can be influenced by monoclonal antibodies in human clinical trials has been on aggregate size and the ease of disruption of the non-covalent the rise. Often monoclonal antibodies require relatively high intermolecular interactions at the Subcutaneous site.
Load more

Recommended publications
  • Joy Wellness Partners 838 W G Street Suite 201 San Diego, California 92101
    United States of America FEDERAL TRADE COMMISSION Southwest Region 1999 Bryan St., Ste. 2150 Dallas, Texas 75201 June 3, 2020 WARNING LETTER VIA EMAIL TO [email protected] Joy Wellness Partners 838 W G Street Suite 201 San Diego, California 92101 Re: Unsubstantiated Claims for Coronavirus Prevention or Treatment To Whom It May Concern, This is to advise you that FTC staff reviewed your website at https://joywellnesspartners.com/ on May 24, 2020. We have determined that you are unlawfully advertising that certain products treat or prevent Coronavirus Disease 2019 (COVID-19). Some examples of Coronavirus treatment or prevention claims on your website include: In marketing materials accessible on your website by selecting “BLOG” from the navigation menu and clicking on “CORONAVIRUS (COVID-19),” you claim: o Under the heading “Hormones, Peptides, & Immunity”: . You state that “Keeping your immune system running optimally with balanced hormones and peptides helps your body prevent and fight illness, including viruses like COVID-19. Book now [https://intakeq.com/booking/8hkwjk]” . You post a video titled “IMMUNITY, BIOTE, & CORONAVIRUS” featuring Carol Joy Bender, NP. In the video at approximately 31:55, Bender states, “More specifically, I wanted to touch on the things that we’re all concerned about the coronavirus times: what can I do to boost my immune system to keep me healthy? BioTE has already been doing this for us… We have a lot of patients that are already taking their iodine with selenium and zinc. The zinc is one of the mainstay treatments that many of you have read about… zinc helps to reduce the RNA replication inside the cells, when the coronavirus gets in.
    [Show full text]
  • Fig. L COMPOSITIONS and METHODS to INHIBIT STEM CELL and PROGENITOR CELL BINDING to LYMPHOID TISSUE and for REGENERATING GERMINAL CENTERS in LYMPHATIC TISSUES
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date Χ 23 February 2012 (23.02.2012) WO 2U12/U24519ft ft A2 (51) International Patent Classification: AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, A61K 31/00 (2006.01) CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, (21) International Application Number: HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, PCT/US201 1/048297 KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, (22) International Filing Date: ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, 18 August 201 1 (18.08.201 1) NO, NZ, OM, PE, PG, PH, PL, PT, QA, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, (25) Filing Language: English TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, (26) Publication Language: English ZW. (30) Priority Data: (84) Designated States (unless otherwise indicated, for every 61/374,943 18 August 2010 (18.08.2010) US kind of regional protection available): ARIPO (BW, GH, 61/441,485 10 February 201 1 (10.02.201 1) US GM, KE, LR, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, 61/449,372 4 March 201 1 (04.03.201 1) US ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, (72) Inventor; and EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, ΓΓ, LT, LU, (71) Applicant : DEISHER, Theresa [US/US]; 1420 Fifth LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, Avenue, Seattle, WA 98101 (US).
    [Show full text]
  • WO 2015/028850 Al 5 March 2015 (05.03.2015) P O P C T
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date WO 2015/028850 Al 5 March 2015 (05.03.2015) P O P C T (51) International Patent Classification: AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, C07D 519/00 (2006.01) A61P 39/00 (2006.01) BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, C07D 487/04 (2006.01) A61P 35/00 (2006.01) DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, A61K 31/5517 (2006.01) A61P 37/00 (2006.01) HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KN, KP, KR, A61K 47/48 (2006.01) KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, (21) International Application Number: OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, PCT/IB2013/058229 SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, (22) International Filing Date: TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, 2 September 2013 (02.09.2013) ZW. (25) Filing Language: English (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, (26) Publication Language: English GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, (71) Applicant: HANGZHOU DAC BIOTECH CO., LTD UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, [US/CN]; Room B2001-B2019, Building 2, No 452 Sixth TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, Street, Hangzhou Economy Development Area, Hangzhou EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, City, Zhejiang 310018 (CN).
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 9.498,544 B2 Ennis Et Al
    USOO949854.4B2 (12) United States Patent (10) Patent No.: US 9.498,544 B2 Ennis et al. (45) Date of Patent: Nov. 22, 2016 (54) GENETICALLY MODIFIED HUMAN (56) References Cited UMIBILICAL CORD PERVASCULAR CELLS FOR PROPHYLAXIS AGAINST OR U.S. PATENT DOCUMENTS TREATMENT OF BIOLOGICAL, OR 5,158,867 A 10/1992 McNally et al. CHEMICAL AGENTS 5,919,702 A 7/1999 Purchio et al. 6,132,724 A 10/2000 Blum (71) Applicant: Tissue Regeneration Therapeutics 7,122,178 B1 10/2006 Simmons et al. 7,547,546 B2 6/2009 Davies et al. Inc., Toronto (CA) 2003.0161818 A1 8, 2003 Weiss et al. 2004/O136967 A1 7/2004 Weiss et al. 2004/O137612 A1 7/2004 Baksh et al. (72) Inventors: Jane Elizabeth Ennis, Oakville (CA); 2005/OO 19911 A1 1/2005 Gronthos et al. Jeffrey Donald Turner, 2005, 0148074 A1 7/2005 Davies et al. Chute-a-Blondeau (CA); John Edward 2005/O158289 A1 7/2005 Simmons et al. Davies, Toronto (CA) 2005/0281790 A1 12/2005 Simmons et al. 2006, OOO8452 A1 1/2006 Simmons et al. 2006, O193840 A1 8, 2006 Gronthos et al. (73) Assignee: Tissue Regeneration Therapeutics 2006, O199263 A1 9/2006 Auger et al. Inc., Toronto (CA) 2006/0286O77 A1 12/2006 Gronthos et al. 2007/0134205 A1 6/2007 Rosenberg 2008.0020459 A1 1/2008 Baksh et al. (*) Notice: Subject to any disclaimer, the term of this 2008.0113434 A1 5/2008 Davies et al. patent is extended or adjusted under 35 2009/0047277 A1 2/2009 Reed et al.
    [Show full text]
  • Endogenous Peptide Discovery of the Rat Circadian Clock a FOCUSED STUDY of the SUPRACHIASMATIC NUCLEUS by ULTRAHIGH PERFORMANCE TANDEM MASS □ SPECTROMETRY* S
    Research Endogenous Peptide Discovery of the Rat Circadian Clock A FOCUSED STUDY OF THE SUPRACHIASMATIC NUCLEUS BY ULTRAHIGH PERFORMANCE TANDEM MASS □ SPECTROMETRY* S Ji Eun Lee‡§, Norman Atkins, Jr.¶, Nathan G. Hatcherʈ, Leonid Zamdborg‡§, Martha U. Gillette§¶**, Jonathan V. Sweedler‡§¶ʈ, and Neil L. Kelleher‡§‡‡ Understanding how a small brain region, the suprachias- pyroglutamylation, or acetylation. These aspects of peptide matic nucleus (SCN), can synchronize the body’s circa- synthesis impact the properties of neuropeptides, further ex- dian rhythms is an ongoing research area. This important panding their diverse physiological implications. Therefore, time-keeping system requires a complex suite of peptide unveiling new peptides and unreported peptide properties is hormones and transmitters that remain incompletely critical to advancing our understanding of nervous system characterized. Here, capillary liquid chromatography and function. FTMS have been coupled with tailored software for the Historically, the analysis of neuropeptides was performed analysis of endogenous peptides present in the SCN of the rat brain. After ex vivo processing of brain slices, by Edman degradation in which the N-terminal amino acid is peptide extraction, identification, and characterization sequentially removed. However, analysis by this method is from tandem FTMS data with <5-ppm mass accuracy slow and does not allow for sequencing of the peptides con- produced a hyperconfident list of 102 endogenous pep- taining N-terminal PTMs (5). Immunological techniques, such tides, including 33 previously unidentified peptides, and as radioimmunoassay and immunohistochemistry, are used 12 peptides that were post-translationally modified with for measuring relative peptide levels and spatial localization, amidation, phosphorylation, pyroglutamylation, or acety- but these methods only detect peptide sequences with known lation.
    [Show full text]
  • Modifications to the Harmonized Tariff Schedule of the United States To
    U.S. International Trade Commission COMMISSIONERS Shara L. Aranoff, Chairman Daniel R. Pearson, Vice Chairman Deanna Tanner Okun Charlotte R. Lane Irving A. Williamson Dean A. Pinkert Address all communications to Secretary to the Commission United States International Trade Commission Washington, DC 20436 U.S. International Trade Commission Washington, DC 20436 www.usitc.gov Modifications to the Harmonized Tariff Schedule of the United States to Implement the Dominican Republic- Central America-United States Free Trade Agreement With Respect to Costa Rica Publication 4038 December 2008 (This page is intentionally blank) Pursuant to the letter of request from the United States Trade Representative of December 18, 2008, set forth in the Appendix hereto, and pursuant to section 1207(a) of the Omnibus Trade and Competitiveness Act, the Commission is publishing the following modifications to the Harmonized Tariff Schedule of the United States (HTS) to implement the Dominican Republic- Central America-United States Free Trade Agreement, as approved in the Dominican Republic-Central America- United States Free Trade Agreement Implementation Act, with respect to Costa Rica. (This page is intentionally blank) Annex I Effective with respect to goods that are entered, or withdrawn from warehouse for consumption, on or after January 1, 2009, the Harmonized Tariff Schedule of the United States (HTS) is modified as provided herein, with bracketed matter included to assist in the understanding of proclaimed modifications. The following supersedes matter now in the HTS. (1). General note 4 is modified as follows: (a). by deleting from subdivision (a) the following country from the enumeration of independent beneficiary developing countries: Costa Rica (b).
    [Show full text]
  • Thymosin Hh10 Inhibits Angiogenesis and Tumor Growth by Interfering with Ras Function
    Research Article Thymosin hh10 Inhibits Angiogenesis and Tumor Growth by Interfering with Ras Function Seung-Hoon Lee,1 Myung Jin Son,1,2 Sun-Hee Oh,1 Seung-Bae Rho,1 Kyungsook Park,1 Yung-Jin Kim,2 Mi-Sun Park,1 and Je-Ho Lee1 1Molecular Therapy Research Center, Samsung Medical Center, School of Medicine, Sung Kyun Kwan University, Seoul, Korea and 2Department of Molecular Biology, Pusan National University, Busan, Korea Abstract are a family of highly conserved small peptides that inhibit barbed end actin polymerization by sequestering actin mono- Thymosin h10 is a monomeric actin sequestering protein mers (8). Among them, thymosin h4 and thymosin h10 are the that regulates actin dynamics. Previously, we and others h have shown that thymosin h acts as an actin-mediated two most abundant -thymosins in the mammalian species and 10 coexist in some tissue types at varying ratios (9). Although both tumor suppressor. In this study, we show that thymosin h10 is not only a cytoskeletal regulator, but that it also acts as a peptides share a high degree of sequence homology, they show potent inhibitor of angiogenesis and tumor growth by its distinct patterns of expression in several tissues (10) and play interaction with Ras. We found that overexpressed thymosin different roles during rodent development (11). Recently, the angiogenic effects of several members of the thymosin family of h10 significantly inhibited vascular endothelial growth factor–induced endothelial cell proliferation, migration, peptides were studied in the chick chorioallantoic membrane h a invasion, and tube formation in vitro. Vessel sprouting was model (12).
    [Show full text]
  • The Two Tontti Tudiul Lui Hi Ha Unit
    THETWO TONTTI USTUDIUL 20170267753A1 LUI HI HA UNIT ( 19) United States (12 ) Patent Application Publication (10 ) Pub. No. : US 2017 /0267753 A1 Ehrenpreis (43 ) Pub . Date : Sep . 21 , 2017 ( 54 ) COMBINATION THERAPY FOR (52 ) U .S . CI. CO - ADMINISTRATION OF MONOCLONAL CPC .. .. CO7K 16 / 241 ( 2013 .01 ) ; A61K 39 / 3955 ANTIBODIES ( 2013 .01 ) ; A61K 31 /4706 ( 2013 .01 ) ; A61K 31 / 165 ( 2013 .01 ) ; CO7K 2317 /21 (2013 . 01 ) ; (71 ) Applicant: Eli D Ehrenpreis , Skokie , IL (US ) CO7K 2317/ 24 ( 2013. 01 ) ; A61K 2039/ 505 ( 2013 .01 ) (72 ) Inventor : Eli D Ehrenpreis, Skokie , IL (US ) (57 ) ABSTRACT Disclosed are methods for enhancing the efficacy of mono (21 ) Appl. No. : 15 /605 ,212 clonal antibody therapy , which entails co - administering a therapeutic monoclonal antibody , or a functional fragment (22 ) Filed : May 25 , 2017 thereof, and an effective amount of colchicine or hydroxy chloroquine , or a combination thereof, to a patient in need Related U . S . Application Data thereof . Also disclosed are methods of prolonging or increasing the time a monoclonal antibody remains in the (63 ) Continuation - in - part of application No . 14 / 947 , 193 , circulation of a patient, which entails co - administering a filed on Nov. 20 , 2015 . therapeutic monoclonal antibody , or a functional fragment ( 60 ) Provisional application No . 62/ 082, 682 , filed on Nov . of the monoclonal antibody , and an effective amount of 21 , 2014 . colchicine or hydroxychloroquine , or a combination thereof, to a patient in need thereof, wherein the time themonoclonal antibody remains in the circulation ( e . g . , blood serum ) of the Publication Classification patient is increased relative to the same regimen of admin (51 ) Int .
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2017/0172932 A1 Peyman (43) Pub
    US 20170172932A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2017/0172932 A1 Peyman (43) Pub. Date: Jun. 22, 2017 (54) EARLY CANCER DETECTION AND A 6LX 39/395 (2006.01) ENHANCED IMMUNOTHERAPY A61R 4I/00 (2006.01) (52) U.S. Cl. (71) Applicant: Gholam A. Peyman, Sun City, AZ CPC .......... A61K 9/50 (2013.01); A61K 39/39558 (US) (2013.01); A61K 4I/0052 (2013.01); A61 K 48/00 (2013.01); A61K 35/17 (2013.01); A61 K (72) Inventor: sham A. Peyman, Sun City, AZ 35/15 (2013.01); A61K 2035/124 (2013.01) (21) Appl. No.: 15/143,981 (57) ABSTRACT (22) Filed: May 2, 2016 A method of therapy for a tumor or other pathology by administering a combination of thermotherapy and immu Related U.S. Application Data notherapy optionally combined with gene delivery. The combination therapy beneficially treats the tumor and pre (63) Continuation-in-part of application No. 14/976,321, vents tumor recurrence, either locally or at a different site, by filed on Dec. 21, 2015. boosting the patient’s immune response both at the time or original therapy and/or for later therapy. With respect to Publication Classification gene delivery, the inventive method may be used in cancer (51) Int. Cl. therapy, but is not limited to such use; it will be appreciated A 6LX 9/50 (2006.01) that the inventive method may be used for gene delivery in A6 IK 35/5 (2006.01) general. The controlled and precise application of thermal A6 IK 4.8/00 (2006.01) energy enhances gene transfer to any cell, whether the cell A 6LX 35/7 (2006.01) is a neoplastic cell, a pre-neoplastic cell, or a normal cell.
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2015/0250896 A1 Zhao (43) Pub
    US 20150250896A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2015/0250896 A1 Zhao (43) Pub. Date: Sep. 10, 2015 (54) HYDROPHILIC LINKERS AND THEIR USES Publication Classification FOR CONUGATION OF DRUGS TO A CELL (51) Int. Cl BNDING MOLECULES A647/48 (2006.01) (71) Applicant: Yongxin R. ZHAO, Henan (CN) Ek E. 30.8 C07D 207/216 (2006.01) (72) Inventor: R. Yongxin Zhao, Lexington, MA (US) C07D 40/12 (2006.01) C07F 9/30 (2006.01) C07F 9/572 (2006.01) (73) Assignee: Hangzhou DAC Biotech Co., Ltd., (52) U.S. Cl. Hangzhou City, ZJ (CN) CPC ........... A61K47/48715 (2013.01); C07F 9/301 (2013.01); C07F 9/65583 (2013.01); C07F (21) Appl. No.: 14/432,073 9/5721 (2013.01); C07D 207/46 (2013.01); C07D 401/12 (2013.01); A61 K3I/454 (22) PCT Filed: Nov. 24, 2012 (2013.01) (86). PCT No.: PCT/B2O12/0567OO Cell(57) binding- agent-drugABSTRACT conjugates comprising hydrophilic- S371 (c)(1), linkers, and methods of using Such linkers and conjugates are (2) Date: Mar. 27, 2015 provided. Patent Application Publication Sep. 10, 2015 Sheet 1 of 23 US 2015/0250896 A1 O HMDS OSiMe 2n O Br H-B-H HPC 3 2 COOEt essiop-\5. E B to NH 120 °C, 2h OsiMe3 J 50 °C, 2h eSiO OEt 120 oC, sh 1 2 3. 42% from 1 Bra-11a1'oet - Brn 11-1 or a 1-1 or ÓH 140 °C ÓEt ÓEt 4 5 6 - --Messio. 8 B1a-Br aus 20 cc, hP-1}^-'ot Br1-Y.
    [Show full text]
  • Multiple Beneficial Effects of Melanocortin MC4 Receptor
    View metadata, citation and similar papers at core.ac.uk brought to you by CORE provided by Archivio della ricerca - Università degli studi di Napoli Federico II Progress in Neurobiology 148 (2017) 40–56 Contents lists available at ScienceDirect Progress in Neurobiology journal homepage: www.elsevier.com/locate/pneurobio Review article Multiple beneficial effects of melanocortin MC4 receptor agonists in experimental neurodegenerative disorders: Therapeutic perspectives a a a b c Daniela Giuliani , Alessandra Ottani , Laura Neri , Davide Zaffe , Paolo Grieco , d e f a, Jerzy Jochem , Gian Maria Cavallini , Anna Catania , Salvatore Guarini * a Department of Biomedical, Metabolic and Neural Sciences, Section of Pharmacology and Molecular Medicine, University of Modena and Reggio Emilia, Modena, Italy b Department of Biomedical, Metabolic and Neural Sciences, Section of Human Morphology, University of Modena and Reggio Emilia, Modena, Italy c Department of Pharmacy, University of Napoli “Federico II”, Napoli, Italy d Department of Basic Medical Sciences, School of Public Health in Bytom, Medical University of Silesia, Katowice, Poland e Department of Ophthalmology, University of Modena and Reggio Emilia, Modena, Italy f Center for Preclinical Surgical Research, Fondazione IRCCS Ca' Granda À Ospedale Maggiore Policlinico, Milano, Italy A R T I C L E I N F O A B S T R A C T Article history: Received 20 May 2015 Melanocortin peptides induce neuroprotection in acute and chronic experimental neurodegenerative Received in revised form 22 November 2016 conditions. Melanocortins likewise counteract systemic responses to brain injuries. Furthermore, they Accepted 28 November 2016 promote neurogenesis by activating critical signaling pathways. Melanocortin-induced long-lasting Available online 1 December 2016 improvement in synaptic activity and neurological performance, including learning and memory, sensory-motor orientation and coordinated limb use, has been consistently observed in experimental Keywords: models of acute and chronic neurodegeneration.
    [Show full text]
  • Supporting Information for Proteomics DOI 10.1002/Pmic.200700142
    Supporting Information for Proteomics DOI 10.1002/pmic.200700142 Karl Skld, Marcus Svensson, Mathias Norrman, Benita Sjgren, Per Svenningsson and Per E. Andren´ The significance of biochemical and molecular sample integrity in brain proteomics and peptidomics: Stathmin 2-20 and peptides as sample quality indicators ª 2007 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim www.proteomics-journal.com SUPPORTING INFORMATION Supporting Information Table 1. Degraded protein identities and peptide sequences in the striatum after 1, 3, and 10 min post-mortem. UniProtKBa. Protein name Sequenceb Scorec P60710/P63260 Actin, cytoplasmic 1,2 A.LVVDNGSGMCK.A 56 E.MATAASSSSLEKS.Y 55 W.IGGSILASLSTFQQ.M 64 W.ISKQEYDESGPSIVHRK.C 93 M.WISKQEYDESGPSIVHRK.C 56 Q8K021 Secretory carrier-associated F.ATGVMSNKTVQTAAANAASTAATSAAQNAFKGNQM.- 124 membrane protein 1 Q9D164 FXYD domain-containing ion L.ITTNAAEPQK.A 58 transport regulator 6 precursor L.ITTNAAEPQKA.E 57 L.ITTNAAEPQKAE.N 89 L.ITTNAAEPQKAEN.- 54 P99029 Peroxiredoxin 5, mitochondrial M.APIKVGDAIPSVEVF.E 57 precursor P01942 Hemoglobin alpha subunit F.LASVSTVLTSKYR.- 106 M.FASFPTTKTYFPHF.D 72 L.ASHHPADFTPAVHASLDK.F 76 T.LASHHPADFTPAVHASLDK.F 59 L.LVTLASHHPADFTPAVHAS.L 56 L.LVTLASHHPADFTPAVHASLDK.F 71 L.LVTLASHHPADFTPAVHASLDKFLASVST.V 66 T.LASHHPADFTPAVHASLDKFLAS.V 55 L.VTLASHHPADFTPAVHASLDKFLAS.V 68 -.VLSGEDKSNIKAAWGKIGGHGAEYGAEALER.M 97 -.VLSGEDKSNIKAAWGKIGGHGAEYGAEALERM.F 58 P02088/P02089 Hemoglobin beta-1,2 subunit L.LVVYPWTQRY.F 53 L.LVVYPWTQRYF.D 52 Q00623 Apolipoprotein A-I precursor Y.VDAVKDSGRDYVSQFESSSLGQQLN.L
    [Show full text]